Skip to main content
OpenTrials
Completed

NCT Number: NCT07472036

Improving Breast Cancer Screening Uptake Through Tailored Reminder Letters

The goal of this trial is to learn whether a culturally and linguistically tailored reminder letter can increase participation in the Flemish Breast Cancer Screening Program among women who previously did not attend screening. The study also examines whether the effect differs between socioeconomic groups.

The main questions it aims to answer are:

* Does a tailored reminder letter increase participation among previous non-attenders? * Does the effect differ between women with lower and higher socioeconomic status?

Researchers compare two groups:

* Intervention group: receive the standard invitation letter plus an additional tailored reminder letter. * Control group: receive the standard invitation letter only.

Participation in screening within 40 days of the invitation is measured using the program's registry.

Participants are women aged 50-69 years who had previously been invited but had never attended screening. The reminder letter is sent as part of routine screening communication, and no additional medical procedures are involved.

Completed

Looking for future studies?

Notify Me

Key information

Age range

50 year–69 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Antwerp, Antwerp, Belgium

Loading trial locations.

About this study

This study aims to evaluate the effectiveness of a culturally and linguistically tailored reminder letter in increasing mammography uptake within the Flemish Breast Cancer Screening Program (BCSP) among women who previously did not attend screening. The objectives are to:

  • Quantify the difference in uptake between the intervention and control arms; and
  • Assess whether the effect differs according to socioeconomic status (SES).

Study Setting:

The study is embedded within the Flemish BCSP, which is coordinated by the Centre for Cancer Detection (CvKO). The BCSP provides biennial screening mammography, free of charge, to eligible individuals aged 50-69 years registered as female in the Belgian national registry. Recruitment occurs through the routine program invitation process, where eligible individuals receive a mailed invitation letter indicating the time and location of their screening appointment.

Study design:

This study is a two-arm, parallel-group, superiority, randomized controlled trial (RCT) with partial blinding.

Study arms:

  • Intervention arm: Participants allocated to the intervention arm receive two mailed communications: (1) the standard BCSP invitation letter, and (2) a tailored reminder letter, specifically designed to address linguistic and cultural barriers that may affect screening participation.
  • Control arm: Participants allocated to the control arm receive the standard BCSP invitation letter only.

Detailed descriptions of study Arms and Intervention, Study Design (Masking, Allocation), Outcome Measures and Eligibility are provided in the designated sections.

Statistical analysis:

The primary analysis compares BC screening uptake between the intervention and control arms in the overall study population. The effect of the intervention is quantified using odds ratios (ORs) with corresponding 95% confidence intervals (CIs). Statistical significance is assessed using the likelihood-ratio chi-square test (x²), with two-sided p-value < 0.05. Stratified analyses are conducted by socioeconomic status (SES), age group, province of residence, and type of mammographic unit. Analyses are performed according to both intention-to-treat (ITT) and per-protocol (PP) principles, with ITT as the primary analytic approach and PP as a sensitivity analysis. The ITT population comprises all randomized participants, excluding records removed before analysis during routine quality control procedures (e.g., duplicate system entries or invalid identifiers). The PP population comprises participants who receive the allocated intervention as planned and for whom complete outcome data is available. Exclusion criteria for the PP analysis comprise withdrawal or opt-out from the BCSP prior to receipt of the assigned communication strategy and documented logistical issues affecting letters delivery in either study arm. Deaths or emigrations occurring prior to participation are not specifically addressed in the PP definition as they are assumed to be evenly distributed between study arms, in line with routine cross-checks with demographic registries. No multivariable adjusted analyses are performed. Stratified analyses are interpreted descriptively, and no formal correction for multiple comparisons is applied.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Individual-level criteria:

  • Aged 50-69 years
  • Legally registered as female in the Belgian national population registry
  • No history of breast cancer in the previous 10 years
  • No bilateral mastectomy in the previous 10 years
  • Invited for mammography between April and June 2024
  • Classified as a non-attender, defined as (1) having received at least one previous screening invitation, and (2) never having participated in the screening program.

Area-level criteria:

To increase the inclusion of socioeconomically vulnerable individuals while maintaining representation from the broader screening population, participants are selected from the list of individuals invited at mammographic units located in municipalities with high deprivation scores, defined as meeting at least two of the following criteria:

  • Average income per capita < EUR 20,000
  • Belgian Multiple Index of Deprivation score < 6
  • Proportion of residents eligible for increased reimbursement for medical expenses > 12%.

Exclusion criteria

  • Actively opted out of the screening program at the time of the study
  • Invited for screening in the previous year
  • Underwent mammographic screening in the previous year

Treatment and study plan

Tailored reminder letter

Behavioral

The intervention development process is described in detail elsewhere (DOI: 10.1186/s13690-025-01591-7). A brief summary is provided below:

The tailored reminder letter was developed using an iterative, participatory approach between April and October 2023. Three focus group discussions with 19 eligible women identified barriers to screening participation and limitations of the existing invitation letter. Based on these findings, a draft letter was refined through a Delphi process involving experts and stakeholders familiar with the screening program and target population. The letter was then improved during a co-creation session with 14 eligible women and validated through a final expert member check.

The final reminder letter was designed for a low-literate audience, using simplified language and visual elements. It included essential appointment information and a QR code linking to translations in multiple languages to improve accessibility for linguistically diverse populations.

Primary outcomes

  1. Screening uptake

    Time frame: Within 40 days after invitation letter is sent.

    Screening uptake, defined as the proportion of invited individuals who attend a mammographic appointment within the pre-specified time frame.

Sponsors and collaborators

Lead sponsor

Universiteit Antwerpen

Other

Collaborators

  • Centre for Cancer Detection (CvKO)
  • Intermutualistic Agency
  • Stichting tegen Kanker
  • Thomas More University of Applied Sciences

Registry information

Official study title

Equity in Breast Cancer Screening in Flanders: the Necessity of Tailored Reminders for Women With Low Socioeconomic Status

Acronym: ENTER

Important dates

Study start
2024
Primary completion
2024
Study completion
2025
First posted
Mar 16, 2026
Registry last updated
Mar 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.